About TAI Diagnostics
TAI Diagnostics is a Healthcare company based in Milwaukee (United States) founded in 2013. Diagnostic solutions for monitoring transplant rejection are provided. TAI Diagnostics has raised $21.11 million across 2 funding rounds from investors including United Therapeutics and Venture Investors. The company has 30 employees. Its focus areas include Life Sciences, Immunology, In Vitro Diagnostic Tests and GvHD. Its competitors include Guardant Health, GRAIL and Thrive Earlier Detection; 3 of its 3 listed competitors have raised funding.
Company details
TAI Diagnostics was founded in 2013 in Milwaukee, United States, within the healthcare diagnostics sector. Non-invasive blood tests are offered to monitor heart transplant patients for organ rejection by measuring cell-free DNA levels from the donor organ. Operations focus on transplant patient care, with the founding team having prior experience at Ariosa Diagnostics, which was acquired by Roche. Services target improved post-transplant outcomes through accessible diagnostics.
- Headquarters Milwaukee, United States
- Employees 30
- SectorsHealthcare
- Website taidiagnostics.com
- Legal Name Tai Diagnostics
- Total Equity Funding$21.11M (USD)
in 2 rounds
- Latest Funding Round$12.83M (USD), Series A
Jun 2018
- InvestorsUnited Therapeutics
& 1 more
- Employee Count30
Funding Insights of TAI Diagnostics
TAI Diagnostics has successfully raised a total of $21.11M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $12.83 million completed in June 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $21.11M
- Total Rounds 2
- Last Round Series A — $12.83M
- First Round $8.28M
(Oct 2015)
- Investors Count 2
All 2 funding rounds of TAI Diagnostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2018 | $12.83M | Series A | – | – | |
| Oct 2015 | $8.28M | Series A | – | Venture Investors | – |
2 investors in total: 2 institutional.
Investors in TAI Diagnostics
TAI Diagnostics has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include United Therapeutics and Venture Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multiple sectors focused seed & early stage VC firm investing in the US, Europe & Asia | ventureinvestors.com | Madison, United States | ||
Treatments for chronic and life-threatening diseases are developed and commercialized. | 1998 | unither.com | Silver Spring, United States |
Investor details for TAI Diagnostics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of TAI Diagnostics
3 dated milestones of TAI Diagnostics across 5 years, from founding to its latest funding, stage changes and deals.
- Founded TAI Diagnostics is founded.
- Funding First funding round of $8.3M.
- Funding Latest funding round, Series A, of $12.8M.
Competitors of TAI Diagnostics
TAI Diagnostics has 3 listed competitors in our database, 3 of them funded. They include Guardant Health, GRAIL and Thrive Earlier Detection.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| grail.com | 2016 | Menlo Park, United States | $2B | 491 | Circulating tumor DNA is screened for early cancer detection. | |
| thrivedetect.com | 2019 | Cambridge, United States | $367M | 138 | Blood-based liquid biopsy tests for multiple cancer detection are provided. |
Detailed competitors of TAI Diagnostics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as TAI Diagnostics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Tai Diagnostics
Complete news archive for TAI Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about TAI Diagnostics
TAI Diagnostics was founded in 2013 and raised its 1st funding round 2 years after it was founded.
TAI Diagnostics is headquartered in Milwaukee, United States. It is registered at Milwaukee, Wisconsin, United States.
TAI Diagnostics is a funded company, having raised a total of $21.11M across 2 funding rounds to date. The company's 1st funding round was a Series A of $8.28M, raised on Oct 2015.
TAI Diagnostics has 30 employees.
TAI Diagnostics was founded in 2013 in Milwaukee, United States, within the healthcare diagnostics sector. Non-invasive blood tests are offered to monitor heart transplant patients for organ rejection by measuring cell-free DNA levels from the donor organ. Operations focus on transplant patient care, with the founding team having prior experience at Ariosa Diagnostics, which was acquired by Roche. Services target improved post-transplant outcomes through accessible diagnostics.
TAI Diagnostics's top competitors include Guardant Health, GRAIL and Thrive Earlier Detection.
TAI Diagnostics has 2 investors. Key investors include United Therapeutics, and Venture Investors.
TAI Diagnostics operates through Tai Diagnostics.